Sunitinib in Patients With Breast Cancer With FGFR1 or FGFR2 Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study.

doi:10.1200/PO.23.00513

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Sunitinib in Patients With Breast Cancer With FGFR1 or FGFR2 Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study.

JCO precision oncology - 1 Feb 2024

Calfa Carmen J, Rothe Michael, Mangat Pam K, Garrett-Mayer Elizabeth, Ahn Eugene R, Burness Monika L, Gogineni Keerthi, Rohatgi Nitin, Al Baghdadi Tareq, Conlin Alison, Gaba Anu, Hamid Omid, Krishnamurthy Jairam, Gavini Naga Jyothi, Gold Philip J, Rodon Jordi, Rueter Jens, Thota Ramya, Grantham Gina N, Hinshaw Dominique C, Gregory Abigail, Halabi Susan, Schilsky Richard L

Abstract excerpt

PURPOSE: The Targeted Agent and Profiling Utilization Registry Study is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and genomic alterations known to be drug targets. Results from cohorts of patients with metastatic breast cancer (BC) with FGFR1 and FGFR2 alterations treated with sunitinib are reported. METHODS: Eligible...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Breast Neoplasms

Share to FGFR1 gene

Share to Mutation

Share to Progression-Free Survival

Share to Receptor, Fibroblast Growth Factor, Type 1

Share to Receptor, Fibroblast Growth Factor, Type 2

Share to Sunitinib

Source

Open in PubMed

Identifiers

PMID: 38354330
DOI: 10.1200/PO.23.00513

Genes

FGFR1
FGFR2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sunitinib in Patients With Breast Cancer With FGFR1 or FGFR2 Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study.PMID 38354330Read ↗

Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study.Semantic proximity Read ↗

Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial.Semantic proximity Read ↗

Afatinib for Advanced Cancers Carrying an EGFR, HER2, or HER3 Mutation: An Open-Label, Phase II, Belgian Precision Study.Semantic proximity Read ↗

Rationale for targeting fibroblast growth factor receptor signaling in breast cancer.Semantic proximity Read ↗

Talazoparib in Patients With Solid Tumors With BRCA1/2 Mutation: Results From the Targeted Agent and Profiling Utilization Registry Study.Semantic proximity Read ↗

Outcomes of patients treated by FGFR inhibitors according to alteration types: An agnostic monocentric retrospective cohort.Semantic proximity Read ↗

FGFR gene amplification and response to HER2-targeted therapy in patients with HER2-expressing metastatic breast cancerSemantic proximity Read ↗

Temsirolimus in Patients With Solid Tumors With PIK3CA Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.Semantic proximity Read ↗

Phase II Study of Sunitinib in Tumors With c-KIT Mutations: Results From the NCI MATCH ECOG-ACRIN Trial (EAY131) Subprotocol V.Semantic proximity Read ↗

Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancerSemantic proximity Read ↗

A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors.Semantic proximity Read ↗

Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.